ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive ...

In a clinical practice guideline issued by the American College of Cardiology, the American Heart Association, and nine other leading medical associations, updated recommendations are presented for ...

ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...

ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of ...

The full guideline included 28 recommendations for which there is the greatest evidence and 141 practice points, which reflect the expert opinion of the group. HealthDay News — In a 2024 clinical ...

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical ...

Although the literature has investigated utilization management practices, how they align with clinical practice guidelines is not well understood. 10, 11 A better understanding of this alignment ...

First developed in the 1960s, they are supported by extensive clinical evidence and recommended by leading professional ...

Please provide your email address to receive an email when new articles are posted on . Key points covered in the guideline include CKD evaluation and classification. The recommendation also offers ...

Visit NAP.edu/10766 to get more information about this book, to buy it in print, or to download it as a free PDF. Clinicians can no longer stay abreast of the rapidly expanding knowledge bases related ...